Dupilumab
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Dupilumab
Dupilumab is a pre-clinical stage product being developed by Regeneron Pharmaceuticals for Food Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT06631677. Target conditions include Food Allergy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
17 competing products in Food Allergy